徐州医科大学
Xuzhou Medical University
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 9 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 9
- 牵头的试验
- 2
- 占中国试验的比例
- 0.3%
- 占全球论文的比例
- 0.3%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- A prognostic nomogram for patients with III-IV nasopharyngeal carcinoma based on dynamic changes in the inflammatory and nutrition index.
- A case of nasopharyngeal carcinoma presenting as Susac syndrome.
- Epigenetic regulation of TIPE3 in nasopharyngeal carcinoma and its impact on the hedgehog signaling pathway.
- Collagen alpha-5(IV) chain activation by nuclear factor 1/C promotes nasopharyngeal carcinoma progression.
- Chitinase 3 like-1 activates the Akt pathway, inducing NF-κB-dependent release of pro-inflammatory cytokines and promoting the proliferative ability in nasopharyngeal carcinoma cells.
ClinicalTrials.gov 上的试验2
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 19 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 19
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- IL-6 is a prognostic biomarker in patients with advanced esophageal squamous cell carcinoma received with PD-1 inhibitors.
- Inhibition of 6-phosphogluconate dehydrogenase suppresses esophageal squamous cell carcinoma growth and enhances the anti-tumor effects of metformin via the AMPK/mTOR pathway.
- Esophageal squamous cell carcinoma derived sEV-PDL1 exhausts CD8+T cells to promote immunosuppression.
- Saikosaponin D suppresses esophageal squamous cell carcinoma via the PI3K-AKT signaling pathway.
- Molecular Mechanism of WWOX Inhibiting the Development of Esophageal Cancer by Inhibiting Hippo Signaling Pathway.
ClinicalTrials.gov 上的试验6
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 76 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 76
- 牵头的试验
- 1
- 占中国试验的比例
- 0.07%
- 占全球论文的比例
- 0.3%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Tumor-produced ammonia is metabolized by regulatory T cells to further impede anti-tumor immunity.
- System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma.
- P21-activated kinase 5 potentiates the chemoresistant phenotype of liver cancer.
- Symptom Cluster Trajectories Among Patients With Hepatocellular Carcinoma After Partial Hepatectomy: A Longitudinal Study.
- Development and validation of a cross-modality tensor fusion model using multi-modality MRI radiomics features and clinical radiological characteristics for the prediction of microvascular invasion in hepatocellular carc
ClinicalTrials.gov 上的试验5
- Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
- β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
- ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 56 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 56
- 牵头的试验
- 1
- 占中国试验的比例
- 0.07%
- 占全球论文的比例
- 0.3%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Development and External Validation of a CT-Based Radiomics Nomogram to Predict Perineural Invasion and Survival in Gastric Cancer: A Multi-institutional Study.
- The association between psychological status and the development of early gastric cancer from atrophic gastritis.
- Radiomics-based assessment of HER2 status and prognosis in gastric cancer: a retrospective dual-center CT study.
- Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy.
- Analysis of multiple factors influencing the survival of patients with advanced gastric cancer.
ClinicalTrials.gov 上的试验6
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
- A Phase 2 Clinical Study of ABSK061 and ABSK043
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 13 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 13
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- A meta-analysis of the efficacy and safety of first-line chemotherapeutic agents for osteosarcoma.
- iNOS Promotes the Development of Osteosarcoma via Wnt/β-Catenin Pathway.
- Bimetallic nanoconjugate hijack Fe-S clusters to drive a closed-loop cuproptosis-ferroptosis strategy for osteosarcoma inhibition.
- Rotenone inhibited osteosarcoma metastasis by modulating ZO-2 expression and location via the ROS/Ca2+/AMPK pathway.
- Deciphering programmed cell death mechanisms in osteosarcoma for prognostic modeling.
神经母细胞瘤
Neuroblastoma2021–2025年中国大陆共有 1,132 篇该病的 PubMed 英文论文,这里牵头了其中 6 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 6
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Conventional, diffusion, and dynamic contrast-enhanced MRI findings for differentiating metaplastic Warthin's tumor of the parotid gland.
- Up-regulation of lncRNA WT1-AS ameliorates Aβ-stimulated neuronal injury through modulation of miR-186-5p/CCND2 axis in Alzheimer's disease.
- Tumor necrosis factor-α-induced protein 8-like 2 alleviates morphine antinociceptive tolerance through reduction of ROS-mediated apoptosis and MAPK/NF-κB signaling pathways.
- Midazolam alleviates cellular senescence in SH-SY5Y neuronal cells in Alzheimer's disease.
- 2-BFI Provides Neuroprotection Against Fluorosis by Stabilizing Endoplasmic Reticulum-Mitochondria Contact Sites and Inhibiting Activation of the NLRP3 Inflammasome.
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 46 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 5
- 牵头的研究论文
- 46
- 牵头的试验
- 6
- 占中国试验的比例
- 1.2%
- 占全球论文的比例
- 0.5%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
- Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
- The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy.
- Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.
- Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.
ClinicalTrials.gov 上的试验6
- Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
- Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma
- Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
- Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia (B-ALL)2021–2025年中国大陆共有 225 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 1
- 占中国试验的比例
- 0.4%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验6
- A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.
- Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
- Study of YK012 in B-cell Acute Lymphoblastic Leukemia
- A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
- Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies
再生障碍性贫血
Aplastic anaemia2021–2025年中国大陆共有 412 篇该病的 PubMed 英文论文,这里牵头了其中 6 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(17.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 6
- 牵头的试验
- 1
- 占中国试验的比例
- 1.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Complex association of mean corpuscular volume and outcomes in patients with aplastic anemia treated with cyclosporine A plus androgen or cyclosporine A alone.
- Red blood cell distribution width as a prognostic factor in patients with aplastic anemia treated with cyclosporin A plus androgen or cyclosporine A alone: a retrospective study.
- Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience.
- A comparative study of porcine antihuman lymphocyte globulin versus antithymocyte globulin-fresenius in an allogeneic hematopoietic cell transplantation conditioning regimen for severe aplastic anemia.
- Identifying an AML Prognostic Model Using 10 Marker Genes from Single-Cell Transcriptome and Bulk Transcriptome Analysis.
噬血细胞性淋巴组织细胞增生症
Haemophagocytic lymphohistiocytosis (HLH)2021–2025年中国大陆共有 399 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 1
- 占中国试验的比例
- 2.1%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- Disparity Analysis of Clinical Features and Prognostic Evaluation of Hemophagocytic Lymphohistiocytosis in Pediatric and Adult Patients: A Retrospective Multicenter Study of 525 Cases in HHLWG.
- A Novel Prognostic Index Model for Adult Hemophagocytic Lymphohistiocytosis: A Multicenter Retrospective Analysis in China.
- The Dosage Recommendation of Cyclosporin in Children with Hemophagocytic Lymphohistiocytosis based on Population Pharmacokinetic Model.
重症肌无力
Myasthenia gravis2021–2025年中国大陆共有 499 篇该病的 PubMed 英文论文,这里牵头了其中 13 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.6%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 13
- 牵头的试验
- 1
- 占中国试验的比例
- 1.1%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.
- Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.
- Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
- Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
- The systemic inflammation markers as possible indices for predicting respiratory failure and outcome in patients with myasthenia gravis.
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025年中国大陆共有 264 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.2%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025年中国大陆共有 989 篇该病的 PubMed 英文论文,这里牵头了其中 5 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 5
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- 2,3,5,6-Tetrafluoro-4-Methoxy-Benzamide alleviates idiopathic pulmonary fibrosis through activation of LGALS3-mediated AGE-RAGE signaling pathway.
- CSF3 aggravates acute exacerbation of pulmonary fibrosis by disrupting alveolar epithelial barrier integrity.
- Fatty acid metabolism-related genes in bronchoalveolar lavage fluid unveil prognostic and immune infiltration in idiopathic pulmonary fibrosis.
- PEDF is an antifibrosis factor that inhibits the activation of fibroblasts in a bleomycin-induced pulmonary fibrosis rat model.
- Characterization of the heterogeneity of endothelial cells in bleomycin-induced lung fibrosis using single-cell RNA sequencing.
ClinicalTrials.gov 上的试验6
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis
- A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.05%
牵头的论文3
- Identifying risk loci for FTD and shared genetic component with ALS: A large-scale multitrait association analysis.
- Genetic correlation and gene-based pleiotropy analysis for four major neurodegenerative diseases with summary statistics.
- Type 2 Diabetes Mellitus and Amyotrophic Lateral Sclerosis: Genetic Overlap, Causality, and Mediation.
IgA 肾病
IgA nephropathy2021–2025年中国大陆共有 736 篇该病的 PubMed 英文论文,这里牵头了其中 0 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 0
- 牵头的试验
- 1
- 占中国试验的比例
- 0.9%
- 占全球论文的比例
- 0.0%
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025年中国大陆共有 300 篇该病的 PubMed 英文论文,这里牵头了其中 4 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 4
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文4
- Profiling of circulating T follicular helper and T peripheral helper cell subsets in patients with primary biliary cholangitis.
- Absence of bidirectional causality between primary biliary cholangitis and major depression: A two-sample Mendelian randomization study.
- Endothelin receptor B enhances liver injury and pro-inflammatory responses by increasing G-protein-coupled receptor kinase-2 expression in primary biliary cholangitis.
- β2-Adrenergic Receptor Enhances the Alternatively Activated Macrophages and Promotes Biliary Injuries Caused by Helminth Infection.
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025年中国大陆共有 100 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(7.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%